Key grade 3–5 AEs occurred more frequently in the NPI group than in the NIV group (94 for NPI vs. The median follow-up was 16.0 months (IQR 14.4–18.5) after targeted intervention. The co-primary endpoints were overall survival (OS) and progression-free survival (PFS).
Prospectively maintained databases were reviewed from 2013 to 2018 to assess individuals with treatment-naive PD-L1 MSTS who received NPI (nivolumab 3 mg/kg and ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by nivolumab 3 mg/kg every 2 weeks) or NIV (3 mg/kg every 2 weeks) until disease progression, withdrawal, unendurable, or death.
GOOGLE JIN SHAN CI BA FREE PLUS
The aim of this retrospective study was to assess the efficacy and safety of nivolumab plus ipilimumab (NPI) versus nivolumab alone (NIV) in individuals with treatment-naive programmed death-ligand 1 (PD-L1) positive MSTS.
Currently, the choice of treatment for individuals with metastatic soft tissue sarcomas (MSTS) presents a significant challenge to clinicians.
0 kommentar(er)
